Next Article in Journal
Medications Modulating the Acid Sphingomyelinase/Ceramide System and 28-Day Mortality among Patients with SARS-CoV-2: An Observational Study
Previous Article in Journal
Depressive and Other Adverse CNS Effects of Fluoroquinolones
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Prunella vulgaris L.: An Updated Overview of Botany, Chemical Composition, Extraction Methods, and Biological Activities

by
Mussa E. Zholdasbayev
1,*,
Gayane A. Atazhanova
1,
Safol Musozoda
2 and
Ewa Poleszak
3
1
School of Pharmacy, NJSC “Karaganda Medical University”, Gogol Street, 40, Karaganda 100000, Kazakhstan
2
Department of Pharmaceutical Technology and Pharmacology, Building No. 3, Tajik National University, Rudaki Avenue Street, 17, Dushanbe 734035, Tajikistan
3
Department of Applied and Social Pharmacy, Medical University of Lublin, st. Al. Racławickie 1, 20-059 Lublin, Poland
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2023, 16(8), 1106; https://doi.org/10.3390/ph16081106
Submission received: 26 April 2023 / Revised: 21 July 2023 / Accepted: 25 July 2023 / Published: 4 August 2023
(This article belongs to the Topic Natural Compounds in Plants)

Abstract

:
Prunella vulgaris L. (PV) is a well-known renewable drug resource full of different groups of biologically active substances with a wide range of pharmacological actions and applications in medicine. In this review, we present an updated comprehensive overview of the botany, extracting methods, chemical composition, and pharmacological activity of different parts of PV extracts. As a result of this review, it was found that chemical composition of PV depends on various factors ranging from the part of the plant to the method of extraction. We also highlight extraction methods that have not been previously used for obtaining PV extracts and may have high scientific interest. With this review, we hope to guide present and future professionals and provide possible previously unexplored areas to find new solutions associated with PV plant.

1. Introduction

Nowadays, the reduction of pharmaceutical production costs along with increasing the efficacy, quality and safety of medicines is of great interest. The use of domestic types of medicinal plant raw materials seems to be economically viable for many researchers. The Prunella Vulgaris L. (PV) has a great scientific interest and practical use as well.
Prunella vulgaris L. (Figure 1) is a perennial herbaceous plant of the Lamiaceae/Labiatae family, originally in Europe and Asia as a widespread plant of temperate climate. Currently, it has an extensive range and grows in all temperate regions of the world, including Eurasia, Africa, America, and Australia [1].
It usually grows in low mountains and foothills, forest fringe, sparse birch forests and aspen copses, shrubs, wet and sometimes saline meadows and glades, lake shores and oxbow lakes, riverbed gravel stones, and forest roads [2].
Prunella vulgaris L. has been successfully used as a drug in European and Chinese traditional medicine since ancient times. Prunella vulgaris L. was called a “self-healing” or “all-healing” plant. Prunella vulgaris L. fruits are included in the Chinese Pharmacopoeia [3] and the European Pharmacopoeia [4] in 2017. However, the rest of the PV aerial parts are not included in any country’s pharmacopeia, which makes the plant attractive to scientists.
In Europe, Prunella vulgaris is approved as a nutritional supplement. It is used as a healing and anti-hemorrhagic agent, as well as to treat sore throats, intestinal infection, and diarrhea. In Asia, the spectrum of PV application is slightly different. It is used as an herbal tea to relieve migraine or fever [5]. In addition, PV has successfully been used to treat thyroid dysfunction and mastitis, as well as pulmonary tuberculosis, infectious hepatitis, and arterial hypertension for more than 2000 years [6]. Goiter, dermatitis, and dermal allergy patients are prescribed PV as well. In addition, it exhibits antioxidant, anti-allergic, anti-inflammatory, and antimicrobial activities [7,8]. Some studies have shown its usefulness in treating atopic dermatitis [9] and photoprotection [10].
Various sources include much information about the properties of the PV aerial part, phytochemical composition, and various types of biological activity due to the popularity of using this plant in medicine. Based on this research, it was found that the main identified components of PV are mono- and sesquiterpenoids, phenolic acids, flavonoids, polysaccharides, pentacyclic triterpenes, higher fatty acids, vitamins, nitrogen-containing compounds, tannins, etc. [11] The caffeic and rosmarinic acids of the phenolic acid class are the basic bioactive agents of PV which determine the anti-inflammatory effect and antioxidant activity [8]. Rosmarinic acid is a complex ester of caffeic and 3-(3,4-dihydroxyphenyl) lactic acid, belonging to the secondary metabolites with a broad spectrum of biological activity. It is one of the effective natural antioxidants [12] which can protect against such free radical pathologies as atherosclerosis, ischaemic heart disease, cancer, and radiation sickness [13]. It is believed that rosmarinic acid binds free radicals of oxygen in the extracellular medium [14,15,16]. Ursolic acid has been described as an effective inhibitor of UVA-modulated expression, the upregulation of which is a visible marker of degradation [17]. It is reported that the amount of rosmarinic acid in the PV aerial mass ranges from 16.8 to 44.4 mg/g [5]. The widespread use of rosmarinic acid is limited by its insufficient production, including the limited raw material base and its manufacturing complexity.
Thus, PV is an important medicinal plant, which, due to its value, rich chemical composition, and pharmacological action, attracts the attention of all scientists in the world. In addition, it is a valuable source of phenolic compounds, flavonoids, and rosmarinic acid, and can serve as a widespread, constantly renewable source of raw materials needed for phytopharmacology. Due to a wide range of PV health benefits, our article provides a comprehensive review of the composition and pharmacological activity, methods for obtaining extracts from PV.

2. Botany

Prunella vulgaris is a perennial plant 10–50 cm high. It is green and almost glabrous, and its rhizome is creeping and oblique. The stem is erect, simple, and almost glabrous.
The дeaves oblong or ovate, glabrous or sparsely pubescent, entire, sometimes obscurely serrated, 2–6 cm long. The lower leaves on the petioles are longer than the blades, the upper ones are sessile under the inflorescence. The flowers are located in false whorls, in dense capitate, ovoid or oblong terminal, sometimes lateral inflorescences. Bracts broadly ovate or almost round, about 1 cm long, sessile with a heart-shaped base, long pointed, membranous-reticulate, almost glabrous, rarely pubescent, with cilia along the edge, from red to black-violet.
Its calyx is two-lipped, humpbacked above, usually hairy at the base, sessile, or on a short stalk. The upper lip is almost square and flat with three very short sharp teeth.
The corolla purple is 8–12 mm long, 1.5–2 times as long as the calyx. The corolla tube is straight; the upper lip is broadly obovate, concave, and slightly notched at the apex. The lower lip is shorter than the upper ones with an almost round, sharply dentate middle lobe and small rounded ovoid lateral. The filaments of long stamens are located under anther with a subulate, straight or slightly curved process. The nuts are ovoid and elliptical, 1.5–2 mm long, nearly 1 mm wide, trihedral, flat outside, and shiny. The flowering stage occurs between June–September.
It grows on the meadows, forest edges, and glades in shrubs, river valleys and springs, along ditches along the banks of lakes and reservoirs, near housing, and in gardens and orchards. Prunella vulgaris is totally spread in Caucasus, Central Asia, Western and Eastern Siberia, the Far East, Western Europe, North Africa, the Balkans, Asia Minor, Iran, India, Tibet, Mongolia, China, and Japan. In Kazakhstan, it is found in the Tobolsk-Ishim, Irtysh, Semipalatinsk, and Kokshetau regions, as well as in Ulutau, Altai, Dzungarian Alatau, and Western Tien Shan [18].

3. Extracting Methods of PV

Currently, there are many ways to obtain plant extracts, and each method has its own pros and cons. We reviewed existing methods for obtaining PV extracts and highlighted methods that have not yet previously been used to obtain extracts from PV.
Various extraction methods have been used for PV extraction. Aqueous [19,20,21], methanol [22,23,24,25], ethanol [26,27,28], hexane, and ethyl acetate [29] PV extracts are obtained by traditional methods such as heating, boiling, or refluxing (Table 1). However, the disadvantage of these methods is the loss of flavonoids due to hydrolysis, oxidation, and ionization during extraction, as well as a long extraction time. Currently, there are many alternative modern methods for obtaining extracts from medicinal plants that can solve these problems. Such preparation methods include supercritical [30], accelerated solvent [31], pulsed-electric field [32], enzyme-assisted [33], pressurized liquid extraction [34], ultrasonic [35], and microwave [36] extraction.
Table 1 presents traditional methods of reflux, maceration, and stirring, as well as the efficient extracting methods including ultrasonic, supercritical fluid, and deep eutectic solvent extraction methods which were not previously covered. Ultrasonic extraction is a simple, efficient, and inexpensive alternative to traditional extraction methods. The principle of powerful ultrasound has been associated with the phenomenon of acoustic cavitation, which occurs when high-intensity acoustic waves are generated in a liquid [37]. The extraction mechanism includes two types of physical phenomena: diffusion through the cell walls, and cell content washout after the walls’ destruction [38]. The authors [39] carried out the ultrasonic extraction of PV fruits in order to extract flavonoids in an ultrasonic bath. The extraction parameters are as follows: ethanol extractant from 20 to 60% by volume; liquid/solid ratio from 10:1 to 50:1; the extraction time from 10 to 50 min; and the extraction temperature from 40 to 80 °C. The results showed that the maximum extraction yield of flavonoids by ultrasonic extraction could be 3.62% using 41% (v/v) ethanol as solvent and a liquid to solid ratio of 30:1 (mL/g) for 30.5 min at 79 °C. In addition, the authors carried out ultrasonic extraction of finely ground PV to evaluate its antiulcer [40] and antitumor [41] properties. Therefore, Xia et al. have presented a new method for PV extraction by using deep eutectic solvents [42]. This method uses natural extraction solvents, and it has such advantages as higher efficiency, economy, and environmental protection, as compared with previously reported conventional extraction methods.
Table 1. Methods of extraction of Prunella vulgaris.
Table 1. Methods of extraction of Prunella vulgaris.
MethodPlant PartSolventLiquid/Solid RatioTemperature, °CTimeReferences
RefluxAerial partDI water-1002 h[19]
RefluxHerbDI water-705 h[24]
RefluxHerb70% ethanol2:19-1 h[27]
RefluxHerb95% ethanol-604 h[28]
StirringSeedMethanol3 × 10 mL methanol g−1-30 min[22]
StirringHerbMethanol
Hexane
Ethyl acetate
9:1Room temperature48 h[29]
MacerationLeaves, stems, flowers Methanol
DI water
2:1Room temperature16 h
24 h
[21]
MacerationAerial part80% methanol-Room tempersture-[25]
MacerationWhole plantHexane
Cloroform
Butanol
---[26]
InfusingLeaves of herbal teaDI water1:18015 min[23]
Supercritical fluid extractionFlowers and dried fruit spikes- 302 h[30]
UltrasonicLeaf, spike inflorescenceDI water
70% methanol
10:1601 h[20]
UltrasonicHerbfrom 20 to 60%from 10:1 to 50:1From 40 to 80From 10 to 50[35]
Deep eutectic solvent extractionWater-deep eutectic solvent 15 mL·g−18342 min[38]
The extraction using microwave activation is successfully used in world practice to obtain plant extracts [43,44,45]; however, data on PV microwave extraction have not been found in any of the literature. In this regard, the study in this direction becomes promising and may have a high degree of novelty.

4. Chemical Composition of PV Plant Parts

The chemical composition of PV is quite diverse and rich in various classes of compounds: mono- and sesquiterpenoids, phenolic acids, flavonoids, polysaccharides, pentacyclic triterpenes, higher fatty acids, vitamins, nitrogen-containing compounds, tannins, etc.
We conducted quantitative analysis and found that PV contains a fairly large amount of flavonoids in the glycosidic form (hyperoside, rutoside), as well as identified smaller amounts of aglycones (quercetol, kaempferol, apigenin) [40]. One of the important flavonoids is hyperoside, which alleviates oxidative damage caused by ROS production [46]. Ursolic and oleanolic acids of the triterpenes in PV are the most common, which have antioxidant, antiallergic, anti-inflammatory and antitumor activities [47]. In addition, Li et al. reported [48] that PV polysaccharides are potential antioxidant and immunomodulatory agents for complementary medicine. Prunella vulgaris has been reported to suppress the immune response through immune cell regulation as well [49].
Fazal et al. [50] found that abiotic stresses such as drought, different concentrations of nutrients in the soil, and different light spectra affect the increase in the content of active ingredients, in particular phenolic compounds and flavonoids in PV plants. It has also been defined that the maximum accumulation of the major biologically active substances (BAS) occurs in early flowering. However, high concentrations of BAS are observed from the period of budding through the mass flowering phase. The maximum content of BAS in the aerial part of PV is observed in leaves and inflorescences [51].
We summarized the comparative composition of PV depending on the extracted part of the plant and the selected solvent, described in the literature (Table 2).
Our research topic’s urgency, novelty, and relevance, as well as our 5–10-year literary search, served as the criteria for choosing citation sources in this review. In this regard, new data on chemical constituents from different parts of PV extracts using various solvents, which were not covered earlier in other reviews, have been added to Table 2. The data obtained by the authors of [52,53] showed that rosmarinic acid was the main component of aqueous extracts of PV. To confirm this fact, [52] we additionally carried out the HPLC analysis using a standard sample of rosmarinic acid. It revealed that rosmarinic acid is indeed the main biologically active component of PV.
The authors Isolated two new compounds from the PV seeds extraction, i.e., amolsamic acid A and B, using methanol and found that the main components are rosmarinic and caffeic acids [29]. Another paper [40] published conflicting data on the presence of rosmarinic acid in the methanolic extract of PV seeds.
In the analysis of 50% ethanol extract obtained from the aerial part, five components were identified: chlorogenic, caffeic, and rosmarinic acids, rutin, and quercetin-3-O-glucoside [54]. It was established that the dominant component is rosmarinic acid and the total content of phenolic compounds PV is 65.53 mg/g, whereas the amount of hydroxycinnamic acids is 45.83 mg/g.
Lin et al. found 55 compounds in the PV herb, including 16 flavonoids, 13 phenolic acids, 17 triterpenes, 2 coumarins, and 7 fatty acids [27]. Among them, abscisic acid and daidzein were identified in PV for the first time.
Ozbek et al. obtained methanol, hexane, and ethyl acetate extracts of PV. Two new compounds, i.e., 2-hydroxy-5-methylbenzaldehyde (15.7%) and 5-hydroxymethylfurfural (15.56%), were found in the methanol extract. The hexane extract contained mostly linolenic acid (45.50%), palmitic acid (16.13%), linoleic acid (15.81%), ethyl acetate linoleic acid (14.32%), and palmitic acid (6.21%) [29].
Lin et al. identified 16 components in the PV spike using GC-MS. The basic constituents were squalene (28.03%), linoleic acid (9.96%), and oleic acid (5.51%) [30].
Golembiovska et al. [55] studied the chemical composition of volatile substances of each part of PV (leaves, stems, and roots) grown in Ukraine. They identified 26 hydrocarbons, 13 aldehydes, 10 aromatics, 9 sesquiterpenes, 8 ketones, 7 monoterpenes, 6 acids and esters, and 18 different compounds, where various components predominated in each plant part. According to their study, the main component was squalene, in flowers 164.3 mg/kg, and 156.5 mg/kg in roots.
The result of the total content of phenols in PV seeds is 8.38 ± 0.50 mg/g pyrogallol equivalent (calculated on the dried basis), the share of caffeic acid is 1.85 ± 0.05, and rosmarinic acid is 0.03 ± 0.00% [22]. In addition, according to the data presented by Sárosi et al. [56], the PV seeds are more saturated with phenolic compounds compared to the aerial part.
Tosun et al. studied the effect of various solvents on the total phenolic content (TPC) of PV using the Folin method and defined the order of solvent efficiency: ethyl acetate > acidic acetonitrile > acidic methanol > acidic butanol > acidic water > water > butanol > methanol > acetonitrile > ethyl acetate > acidic hexane > hexane [57]. The TPC of aerial parts of PV aqueous extracts were 90.53 ± 6.81 mg GAE/g [58], and of the whole plant in ethanol, 377.30 ± 12.70 [59].
Mahboubi et al. conducted a study on the content of TPC and total flavonoid content (TFC) of the PV aerial part [60]. The TPC of PV extract was found to be higher in the aqueous extract (156.5 mg GAC/g), while it was (122.1 mg GAC/g) in the ethanol, and (115.7 mg GAC/g) in the methanol ones. The TFC of the PV methanol extract (82.8 mg QE/g) was higher than those of the ethanol extract (22.7 mg QE/g) and the aqueous extract (16.2 mg QE/g). There is an inverse relationship between TPC and TFC based on the choice of solvent. Ahmad G et al. [61] carried out similar studies of the extract obtained from the PV spikes and found that the methanol extract has the highest content of TFC compared to the ethanol and water ones. However, in this study, the evaluation of TPC showed a similar order with TFC, compared to the study mentioned above. This is due to the extraction of different parts of PV which allows us to conclude that the content of TPC and TFC is different.
Therefore, we can conclude that rosmarinic and caffeic acids are the main components and have been found in all parts of PV, which is confirmed by numerous studies in our review. According to the literature data, the chemical composition of PV varies due to the type of solvent, the extractable part of the plant, the method of extracting, and the phase of collection as well. In this regard, there is a great scientific interest in conducting previously unexamined study on the influence of various factors on the chemical composition of PV. According to our viewpoint, there is still no extensive study on the influence of different parameters on the results obtained during extraction of PV, e.g., raw material size, plant part, liquid (solid ratio, solvents), temperature, time, etc. These parameters are important for the chemical composition and following properties of the PV extracts.

5. Biological Activities of PV Extracts

Currently, quite a few reviews on the biological properties of PV have been published [62]; however, PV is a plant that still arouses the interest of scientists. Hence, there are new scientific works which have not been covered earlier, but the results of which we would like to examine in this review. For example, there is some new information on the antiviral activity studies (HIV, HSV, Ebola virus, SARS-coronavirus 2) [63,64,65,66].

5.1. Antiviral Activity

In a recent review, Mark and Walsh [63] have examined articles reporting potent antiviral activity against HIV and HSV of PV. Another review reports the potential use of aqueous solutions of PV against HIV and Ebola virus [64].
There are literature data on the activity of PV against SARS-coronavirus 2 (SCoV-2) virus infection [65]. The authors demonstrated [66] that an aqueous extract of PV and the compound suramin exhibit a potent inhibitory effect on both wild and mutant (G614) pseudotyped SCoV-2-SP-mediated infections. The IC50 for PV and suramin on this type of infection are 30 and 40 µg/mL, respectively. The results of the study showed that the combination of suramin with PV with a neutralizing antibody against SARS-CoV-2 mediated a more powerful blocking effect against SCoV2-SP-PV and therefore can be used as a new antiviral agent against SCoV-2 infection.
Gazanfar et al. conducted a study to assess the hepatoprotective potential of the methanol, aqueous, and ethanol extracts of the PV spike in vivo. Treatment of rats with extracts showed a very significant reduction in serum glutamic oxaloacetic transaminase, serum glutamic pyruvic transaminase, alkaline phosphatase, serum total, and direct bilirubin levels (p < 0.01), and a very significant increase in total protein (p < 0.01) compared to the toxic control group. This was further supported by histopathological evaluation in which the groups treated with extracts and silymarin had an almost normal liver structure or much less liver damage compared to the group treated with paracetamol. The results of biochemical and histopathological evaluation showed that methanol was the most effective among all the extracts [61].

5.2. Antibacterial Activity

Summarized information about the antibacterial activity of PV indicating MIC and MBC with critical attributes is shown in Table 3.
Table 3 presents new references on antibacterial activity [19,29,63]. According to the literature data, the methanol extract of PV has a pronounced antibacterial effect and inhibitory activity against gram-positive bacteria in vitro [8]. Grosan et al. found that methanolic extracts of PV spikes have almost the same antibacterial effect in intensity on both standard strains and clinical isolates (Pseudomonas aeruginosa, Klebsiella pneumoniae) [67]. In addition to the already published literature, it allows us to conclude that the antibacterial effect of methanol extracts is obtained to a greater extent due to methanol itself, and to a lesser extent, due to the extractable active compounds [68].
Komal et al. showed [19] the growth inhibition of 38 resistant isolates of Escherichia coli strains of the PV ethanolic and aqueous extracts in comparison with ciprofloxacin, ofloxacin, cefixime, and tobramycin by the well diffusion method. It has been established that water and alcohol extracts have a positive effect on the multiresistant strain of Escherichia coli, separately and in combination with each other. In this regard, there is likelihood of using PVs as a maintenance therapy in parallel with standard antibiotics used to treat urinary tract infections.
Patel et al. [69], in their study, tested the in vitro methanol and petroleum ether extracts of PV for activity against Bacillus subtilis, Escherichia coli, Staphylococcus aureus, and Salmonella typhi. Similarly, the in vivo studies were conducted by using peritonitis caused by Escherichia coli on laboratory rats where they were given ofloxacin allopathic antibiotics. The results were compared with those rats which were given herbal extracts under controlled conditions. The study has defined that the petroleum ether extracts exhibit the lowest antibacterial activity compared to the methanol extracts. The PV methanolic extracts effectively restrict the growth of Escherichia coli at 100 µg/mL, Bacillus subtilis at 50 µg/mL, and Staphylococcus aureus at 100 µg/mL, while Salmonella typhi showed complete resistance.
In a recent study, [29] the authors have evaluated the antibacterial activity of methanol, ethyl acetate, and hexane extracts of PV against Bacillus cereus, Clostridium perfringens, Staphylococcus aureus, Streptococcus pyogenes, Salmonella typhimurium, Escherichia coli, Serratia marcescens, Klebsiella pneumoniae, Proteus vulgaris, and Pseudomonas aeruginosa. The methanol extract showed the highest antibacterial activity against Bacillus cereus, hexane against Salmonella typhimurium, and ethyl acetate against Streptococcus pyogenes. We can conclude that these extracts can be used in the future as antibacterial agents to prevent diseases associated with these microbial infections.

5.3. Antitumor Activity

The cell count kit-8 (CCK-8) on cancer cells from the SCC154 oral squamous cell carcinoma cell line was used in order to assess the antitumor effect of PV distillate. The PV distillate was found to be cytotoxic for SSC154 cancer cells depending on the dosage [41].
According to the study [70], the main components that determine the antitumor properties of PV are caffeic and rosmarinic acids. In this study, chemotherapy was performed in combination with a taxane for treating patients with breast cancer. The mean follow-up time was 41 months. The PV treatment improved a complete response rate and an overall survival time compared to those in the control group (p < 0.05). The three-year overall survival rates were 86.5 and 77.2% among patients in the experimental and control groups, respectively (p < 0.05). In addition, the PV treatment prevents side effects, namely neutrophil fever and chemotherapy-induced anemia. Therefore, PV may be a potential adjuvant in treating breast cancer.
Our study showed that the extract (concentrated aqueous solution after initial methanol extraction) from the PV spikes had dose- and time-dependent cytotoxic and anti-migratory potential in humans on a tested breast adenocarcinoma cell line, namely MDA-MB-231, and at the same time, affected non-tumor epithelial cells of the mammary gland to a lesser extent [67].
Antitumor activity was also tested by Hwang et al. using HepG2, HT29, A549, MKN45, and HeLa cancer cell lines. The PV ethanol extract (at 50 and 100 µg/mL), hexane fraction (at 100 µg/mL), and chloroform fraction (at 50 and 100 µg/mL) inhibited cell proliferation, but not at 10 µg/mL. Conversely, in groups receiving 10 µg/mL of ethanol extract or butanol fraction or 10, 50, and 100 µg/mL of aqueous fraction, the proliferative effect exceeded 10%. The results showed that the PV ethanol extract caused significant cytotoxic effects on various cancer cell lines [26].
Feng et al. found that a 60% ethanol extract of PV inhibited C57BL/6 mice’s tumor growth, increased superoxide dismutase activity, and reduced serum malondialdehyde levels in tumor-bearing mice. These results indicate that a 60% ethanol extract of PV has a high antioxidant activity both in vitro and in vivo. This extract may play an important role in the prevention and treatment of tumors and be useful as a dietary supplement or an antitumor agent [71].
In vitro, the PV extract has activity against human uterine myoma (UM) cells. It does not show drug toxicity and promotes apoptosis of human UM cells, as well as inhibits the transition of UM cells from the G0/G1 stage to the G2 stage, where the DNA replication occurs. In vivo, PV has an anti-UM activity, reduces estrogen and progesterone concentrations, downregulates estrogen and progesterone receptor expression levels via the estrogen signaling pathway, and promotes UM cell apoptosis by decreasing survivin and Bcl-2 protein expression levels and increasing caspase-3 and Bax expression levels through the mitochondria-mediated pathway of apoptosis [30].

5.4. Antioxidant Activity

Total flavonoid (TFC) content including rosmarinic acid, caffeic acid, and hyperoside directly affects the antioxidant capacity (DPPH• and ABTS•+). Chen et al. [72] revealed a pattern that during the growth of spika, TFC significantly decreased, while the content of salviaflazid increased. Spika had the highest TFC and rosmarinic and caffeic acids, as well as the highest antioxidant activity at the flowering stage, and the highest hyperoside content in a bud-formation period.
An experiment described by Seo et al. [73] with a methanolic extract of PV flowering stems showed a DPPH inhibitory activity of 35.4% and an ABTS inhibitory activity of 61.7% at a concentration of 100 µg/mL. Hwang et al. [26] found that the methanol extract of PV seeds is much more active than the extract obtained from the PV flowering stems.
In this study, the results of the assessment of the PV oxidant effect showed that the ethanol and aqueous extract of PV have a higher content of antioxidants compared to other solvent fractions, similar to their total content of phenols [28]. A 60% ethanol extract of PV showed high activity in removing free radicals in vitro according to the ABTS, DPPH, and FRAP methods [73]. Total phenols strongly correlated with antioxidant activity (R2 = 0.9988 in ABTS•+; 0.6284 in DPPH, and 0.9673 in FRAP tests).
Other authors have obtained different results and found that the organic fraction has a more pronounced antioxidant activity than the aqueous ones. Psotova et al. [8] isolated rosmarinic acid (25.7% w/w) and caffeic acid (0.37%) from the aerial part of PV by the methanol extraction followed by the organic fraction isolation. The IC50 values for rosmarinic and caffeic acids were 1.87 ± 0.06 and 0.81 ± 0.05 mg/mL, respectively.
The study obtained data on a high-antioxidant, antiradical, and low hemolytic activity of 50% PV ethanol extract. Low hemolytic activity is observed in aqueous 25%, as well as in 50% PV leaf extracts. Both 50% and 96% ethanol extracts have high antioxidant activities [74].

5.5. Treatment of Thyroiditis-Associated Diseases

Traditional Chinese medicine has been treating thyroid diseases with PV for thousands of years. There are many studies on a potential therapeutic effect of the PV extracts on autoimmune thyroiditis and other types of thyroiditis-dependent diseases [75]. Serum thyroglobulin antibodies (TgAb) and thyroid volume in rats in an experimental model of autoimmune thyroiditis (EAT) dropped sharply after administrating an aqueous extract of PV spikes. In addition, PV induced indoleamine-2,3 dioxygenase (IDO1) mRNA and protein expression in the spleen and intestines of rat EAT treated with PV [52].
Han et al. conducted 13 randomized clinical trials involving 1468 patients. A meta-analysis has shown that PV in combination with levothyroxine sodium tablets or thyroxine tablets has more benefits in thyroid nodules, further increasing clinical efficacy, reducing the diameter of nodules, and reducing the frequency of adverse reactions [76].
The molecular docking studies have shown that luteolin and kaempferol are BAS of PV which may play an important role in treating Hashimoto’s thyroiditis by regulating several signaling pathways: TNF, MAPK (mitogen-activated protein kinase), and PI3K-Akt [77]. As a result of the KEGG pathway network and target compound analysis, it was found that quercetin, luteolin, kaempferol, and beta-sitosterol are the main BAS in PV, responsible for activity in treating subacute thyroiditis, and are closely associated with their regulation of inflammation and apoptosis by targeting PIK3CG proteins, MAPK1, MAPK14, TNF and PTGS2, and PI3K-Akt and TNF signaling pathways. The study has shown that quercetin, luteolin, kaempferol, and PV beta-sitosterol may play key roles in the treatment of subacute thyroiditis associated with the regulation of inflammation and apoptosis by influencing PI3K-Akt and TNF signaling pathways [78].
The effect of PV polysaccharides on cultured orbital fibroblasts in vitro among the thyroid-associated ophthalmopathy (TAO) patients has been studied as well. Prunella vulgaris polysaccharides have been used in different concentrations to treat different groups of fibroblasts among both TAO patients and healthy ones. Dexamethasone was used as a positive control drug, whereas interferon-γ (IFN-γ) was used as a positive stimulator. The results showed that the PV polysaccharides at concentration above 400 µg/mL significantly inhibited orbital fibroblast proliferation among the TAO patients (p < 0.05). However, no definite inhibitory effect was found in orbital fibroblasts of healthy patients. Prunella vulgaris polysaccharides in combination with dexamethasone in all concentrations can significantly promote apoptosis of orbital fibroblasts when co-cultured with IFN-γ (p < 0.05). Our study results suggest that PV has a therapeutic effect by inhibiting the orbital fibroblast proliferation and promoting apoptosis of orbital fibroblasts among the TAO patients [79].

5.6. Other Activities

Grosan et al. have identified that the hydroalcoholic extracts of PV in an in vivo experiment have a dose-dependent antiulcer effect due to a rich content of polyphenols which have a protective effect for stomach ulcers when taking the non-steroidal anti-inflammatory drugs (NSAIDs) [40].
The aqueous and methanolic extracts of PV were evaluated for anthelmintic efficacy against ovine gastrointestinal nematodes both in vitro and in vivo using the worm motility inhibition assay, egg hatch assay, and faecal egg reduction percentage assay, respectively. The methanol extract (LC50 = 2.48 mg/mL) has a stronger inhibitory effect compared to an egg hatching aqueous extract (LC50 = 3.36 mg/mL) showing a higher ovicidal activity. In vivo the largest reduction of fecal eggs (92.86%) was recorded for a crude methanol extract, followed by a crude aqueous extract (80.34%) at 2 g/kg body weight on the 15th post-treatment day [21]. The present study’s results suggest that the PV extracts are promising alternatives to commercially available anthelmintic agents.
The methanolic PV seed extract showed a strong anti-inflammatory activity on neutrophils, myeloperoxidase, and horseradish peroxidase models. The anti-inflammatory effect of PV seed extract was also characterized by its ability to modulate the myeloperoxidase enzyme activity [22]. The results of the study showed that treatment with PV tea (water extract of leaves) significantly increased inducible nitric oxide synthase and demonstrated anti-inflammatory effects through the 5-lipoxygenase, myeloperoxidase, and nitric oxide synthase pathways [23].
Anti-IHNV (infectious hematopoietic necrosis virus) activity was studied on 32 medicinal plants using cyprini papulosum epithelioma (EPC) cells. Among these plants, PV showed the strongest inhibition of IHNV replication, with a 99.3% inhibition rate at 100 mg/L. In addition, it was found that the IC50 of ursolic acid after 72 h on IHNV is 8.0 μM. In addition, UA can significantly reduce a cytopathic effect and virus titer induced by IHNV in EPC cells [80].
An aqueous methanolic extract of the PV aerial part increased wound strength by 33.9% in a linear wound model and caused a 75.2% contraction on the 12th day in a circular wound model. In a postoperative wound model, the ethyl acetate extract increased wound tensile strength by 39.3%, whereas the 86.3% reduction was found in the excisional wound model on the 12th day [25].
All PV parts have antihypertensive effects in the clinical management of hypertension. An aqueous extract and a water-ethanol (30%) extract of PV reduce animals’ blood pressure [81].
In a study conducted by Lin et al., the results showed that the PV fraction eluted with 70% ethanol had a significant hypnotic effect that shortened sodium pentobarbital-induced mice’s sleep latency (p < 0.01) and prolonged their sleep time (p < 0.01), compared to the control group. In addition, the fraction eluted with water, as well as 20% ethanol, and 95% ethanol (p > 0.05), had no significant differences in comparison with the control group and had no hypnotic effect [27].

6. Dosage Forms and Clinical Applications

In recent years, the PV-based drugs have been of great interest in clinical practice, used both as a separate substance and in combination with other drugs and non-drugs. Currently, PV is used to produce various drugs such as injections, oral liquid, and ointment. As previously reported in this review, drug efficiency will depend on the PV extraction methods, the type of solvent used, and the technological process as well.
According to the Order of the Ministry of Health of the Republic of Belarus, dated February 25, 1998, No. 56, PV is included in the Nomenclature of Homeopathic Medicines. PV is an active ointment substance for treating burns [82]. It is included in the Liren Bio-lipopolis anti-cellulite firming gel (Lab. Dr Irena Eris Production), a mixture of plant raw materials used to produce the mammoleptin capsules for treating fibrocystic mammopathy, as well as the Frudia face mask (WelcosCo. LTD Production, South Korea). PV is actively used by manufacturers to produce dietary supplements called Selfheal in the form of tablets, and liquid extracts based on PV (manufacturers: Nature’s Health, Secrets of the Tribe, HawaiiPharm).
In order to be used in the form of tablets, the PV extract is dried and compressed. The drug in this form has a broad spectrum of activity, including good results in the treatment of benign prostatic hyperplasia [83]. The authors conducted taxane chemotherapy together with the oral form of PV, which found high efficacy and safety in treating breast cancer patients [70]. In addition, we have defined that the PV tablets in combination with glucocorticoids have a shorter treatment course and fewer adverse reactions in the treatment of acute thyroiditis [84]. According to a study of thyroiditis by Fan et al., the PV-based capsules in combination with levothyroxine sodium tablets significantly increased thyroid levels, compared to only l-thyroxine-treated patients [85].

7. Conclusions

Relevant PV studies are globally carried out from year to year. Thus, this article summarizes the study status on phytochemistry, vegetation regions, and methods for obtaining pharmacological effects over the last decades. With this review, we hope to guide future professionals in natural plant research and provide possible previously unexplored areas to find new solutions.
First, PV has a rich chemical composition, including triterpenoids and their glycosides, flavonoids, phenolic acids and their glycosides, organic acids, sterols, essential oils, polysaccharides, and tannins. However, further studies are needed to understand the plant’s future application, as well as to identify the metabolites responsible for a particular type of activity. According to current global trends, BAS should be extracted and purified using advanced economical and green technologies. For instance, no literature data were found concerning the use of microwave activation to obtain PV extracts. This method is environmentally friendly in terms of reducing the extraction time by 5–20 times compared to traditional ones. The use of microwave extraction has a high scientific potential due to releasing and obtaining new substances, and the quantitative content of BAS from plant raw materials, in particular from PV, which may cause other properties different from the already available data.
Secondly, despite its rich chemical composition and high biological activity, PV is not so widely used in medicine, which causes scientific interest in the development of dosage forms based on PV that have not yet been developed (e.g., an ointment, a gel, a cream, a syrup, powders, suppositories, suspensions, etc.).
Thus, we conclude that PV is a powerful and widespread drug resource with a huge potential for development. Therefore, there is a need to additionally study all aspects of the isolation, preparation, and identification of BAS, extraction methods, solvent selection, and operating conditions for obtaining dosage forms for maximum release, as well as determining quality standards and ensuring product safety.

Author Contributions

Conceptualization, M.E.Z. and G.A.A.; methodology, M.E.Z.; formal analysis, M.E.Z.; investigation, M.E.Z.; resources, G.A.A.; data curation, E.P.; writing—original draft preparation, M.E.Z. and S.M.; writing—review and editing, G.A.A.; visualization, M.E.Z.; supervision, M.E.Z.; project administration, G.A.A. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Science Committee of the Ministry of Science and Higher Education of the Republic of Kazakhstan, grant number—AP15473381: “Development of a new wound-healing, antimicrobial, antioxidant and anti-inflammatory agent based on the terrestrial organs of Prunella vulgaris L.”.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Wang, S.J.; Wang, X.H.; Dai, Y.Y.; Ma, M.H.; Rahman, K.; Nian, H.; Zhang, H. Prunella vulgaris: A Comprehensive Review of Chemical Constituents, Pharmacological Effects and Clinical Applications. Curr. Pharm. Des. 2019, 25, 359–369. [Google Scholar] [CrossRef]
  2. Cheremushkina, V.A.; Barsukova, I.N. Rhythm of seasonal development and small life cycle of Prunella vulgaris L. (Lamiaceae) in Khakassia. J. Sib. Fed. University. Biol. 2020, 13, 94–108. [Google Scholar] [CrossRef] [Green Version]
  3. Commission, C.P. The 2020 Edition of Pharmacopoeia of the People’s Republic of China Volume 1, 11th ed.; Chemical Industry Press: Beijing, China, 2020. [Google Scholar]
  4. Council of Europe. European Pharmacopoeia, 10th ed.; Deutscher Apotheker: Stuttgart, Germany, 2019. [Google Scholar]
  5. Huang, N.; Hauck, C.; Yum, M.Y.; Rizshsky, L.; Widrlechner, M.P.; McCoy, J.A.; Murphy, P.A.; Dixon, P.M.; Nikolau, B.J.; Birt, D.F. Rosmarinic acid in Prunella vulgaris ethanol extract inhibits lipopolysaccharide-induced prostaglandin E2 and nitric oxide in RAW 264.7 mouse macrophages. J. Agric. Food Chem. 2009, 57, 10579–10589. [Google Scholar] [CrossRef] [Green Version]
  6. Bai, Y.; Xia, B.; Xie, W.; Zhou, Y.; Xie, J.; Li, H.; Liao, D.; Lin, L.; Li, C. Phytochemistry and pharmacological activities of the genus Prunella. Food Chem. 2016, 204, 483–496. [Google Scholar] [CrossRef] [PubMed]
  7. Ryu, S.Y.; Oak, M.H.; Yoon, S.K.; Cho, D.I.; Yoo, G.S.; Kim, T.S.; Kim, K.M. Anti-allergic and anti-inflammatory triterpenes from the herb of Prunella vulgaris. Planta Med. 2000, 66, 358–360. [Google Scholar] [CrossRef] [PubMed]
  8. Psotová, J.; Kolár, M.; Sousek, J.; Svagera, Z.; Vicar, J.; Ulrichová, J. Biological activities of Prunella vulgaris extract. Phytother. Res. 2003, 17, 1082–1087. [Google Scholar] [CrossRef] [PubMed]
  9. Lee, J.; Jung, E.; Koh, J.; Kim, Y.S.; Park, D. Effect of rosmarinic acid on atopic dermatitis. J. Dermatol. 2008, 35, 768–771. [Google Scholar] [CrossRef]
  10. Vostálová, J.; Zdarilová, A.; Svobodová, A. Prunella vulgaris extract and rosmarinic acid prevent UVB-induced DNA damage and oxidative stress in HaCaT keratinocytes. Arch. Dermatol. Res. 2010, 302, 171–181. [Google Scholar] [CrossRef]
  11. Pan, J.; Wang, H.; Chen, Y. Prunella vulgaris L.—A Review of its Ethnopharmacology, Phytochemistry, Quality Control and Pharmacological Effects. Front. Pharmacol. 2022, 13, 903171. [Google Scholar] [CrossRef]
  12. Malencic, D.J.; Gasic, O.; Popovic, M.; Boza, P. Screening for antioxidant properties of Salvia reflexa fornem. Phytother. Res. 2000, 14, 546–548. [Google Scholar] [CrossRef]
  13. Badekova, K.Z.; Levaya, Y.K.; Atazhanova, G.A.; Zholdasbayev, M.E. Biological properties of rosmarinic acid. Pharm. Kazakhstan 2020, 7–8, 29–34. [Google Scholar]
  14. Paly, A.E.; Melikov, F.M.; Grebennikova, O.A.; Rabotyagov, V.D. Rosmarinic acid and its raw materials in the Crimea. Pharm. Pharmacol. 2015, 3, 7–12. [Google Scholar] [CrossRef] [PubMed]
  15. al-Sereiti, M.R.; Abu-Amer, K.M.; Sen, P. Pharmacology of rosemary (Rosmarinus officinalis Linn.) and its therapeutic potentials. Indian J. Exp. Biol. 1999, 37, 124–130. [Google Scholar] [PubMed]
  16. Gamaro, G.D.; Suyenaga, E.; Borsoi, M.; Lermen, J.; Pereira, P.; Ardenghi, P. Effect of rosmarinic and caffeic acids on inflammatory and nociception process in rats. ISRN Pharmacol. 2011, 2011, 451682. [Google Scholar] [CrossRef] [Green Version]
  17. Soo Lee, Y.; Jin, D.Q.; Beak, S.M.; Lee, E.S.; Kim, J.A. Inhibition of ultraviolet-A-modulated signaling pathways by asiatic acid and ursolic acid in HaCaT human keratinocytes. Eur. J. Pharmacol. 2003, 476, 173–178. [Google Scholar] [CrossRef]
  18. Nauka. Flora of Kazakhstan, 7th ed.; Nauka: Alma-Ata Kazakhstan, Kazakh, 1964. [Google Scholar]
  19. Komal, S.; Kazmi, S.A.J.; Khan, J.A.; Gilani, M.M. Antimicrobial activity of Prunella vulgaris extracts against multi-drug resistant Escherichia coli from patients of urinary tract infection. Pak. J. Med. Sci. 2018, 34, 616–620. [Google Scholar] [CrossRef] [PubMed]
  20. Groşan, A.; Ștefănescu, R.; Vari, C.E.; Jîtcă, G.; Bătrânu, M.; Muntean, L.D. Phytochemical Characterization of Transilvanian Prunella vulgaris. Acta Biol. Marisiensis 2020, 3, 62–69. [Google Scholar] [CrossRef]
  21. Lone, B.A.; Chishti, M.Z.; Bhat, F.A.; Tak, H.; Bandh, S.A. Anthelmintic Activities of Aqueous and Methanol Extracts of Prunella vulgaris L. Nat. Prod. Chem. Res. 2017, 5, 269. [Google Scholar] [CrossRef]
  22. Danthine, S.; Paul, A.; Jansen, O.; Ducrey, A.; Richel, A.; Lognay, G.; Maesen, P.; Mutwale Kapepula, P.; Mouithys-Mickalad, A.; Franck, T.; et al. Prunella vulgaris L. seeds: A promising source of lipids, proteins, and original phenolic compounds presenting high antioxidant and anti-inflammatory activity. Biotechnol. Agron. Soc. Environ. 2022, 26, 1–15. [Google Scholar] [CrossRef]
  23. Tan, R.; Lai, J.X.; Loke, W.M. Antioxidant and Anti-inflammatory Properties of Prunella vulgaris Tea. Curr. Res. Nutr. Food Sci. 2022, 10, 521–531. [Google Scholar] [CrossRef]
  24. Wu, H.; Gao, M.; Ha, T.; Kelley, J.; Young, A.; Breuel, K. Prunella vulgaris aqueous extract attenuates IL-1β-induced apoptosis and NF-κB activation in INS-1 cells. Exp. Ther. Med. 2012, 3, 919–924. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Küpeli Akkol, E.; Renda, G.; İlhan, M.; Bektaş, N.Y. Wound healing acceleration and anti-inflammatory potential of Prunella vulgaris L.: From conventional use to preclinical scientific verification. J. Ethnopharmacol. 2022, 295, 115411. [Google Scholar] [CrossRef] [PubMed]
  26. Hwang, Y.J.; Lee, E.J.; Kim, H.R.; Hwang, K.A. In vitro antioxidant and anticancer effects of solvent fractions from Prunella vulgaris var. lilacina. BMC Complement Altern Med 2013, 13, 310. [Google Scholar] [CrossRef] [Green Version]
  27. Lin, T.F.; Qiu, J.N.; Zhang, S.; Zhang, Y.; Zhang, Y.; Sun, M.; Zhang, J.H.; Liu, B.; Cheng, F.F.; Jiang, Y.Y. Screening out the anti-insomnia components from Prunella vulgaris L. based on plasma pharmacochemistry combined with pharmacodynamic experiments and UPLC-MS/MS analysis. J Ethnopharmacol 2021, 279, 114373. [Google Scholar] [CrossRef]
  28. Zhang, Z.; Zhou, Y.; Lin, Y.; Li, Y.; Xia, B.; Lin, L.; Liao, D. GC-MS-based metabolomics research on the anti-hyperlipidaemic activity of Prunella vulgaris L. polysaccharides. Int. J. Biol. Macromol. 2020, 159, 461–473. [Google Scholar] [CrossRef] [PubMed]
  29. Özbek, O.; Saglam, B.; Canan Usta, N.; Budak, Y. GC–MS analysis and anti–microbial activity of Prunella vulgaris L. extracts. J. Indian Chem. Soc. 2022, 99, 100460. [Google Scholar] [CrossRef]
  30. Lin, Y.; Yang, C.; Tang, J.; Zhang, Z.; Xia, B.; Li, Y.; Lin, L.; Liao, D. Characterization and anti-uterine tumor effect of extract from Prunella vulgaris L. BMC Complement. Med. Ther. 2020, 20, 189. [Google Scholar] [CrossRef] [PubMed]
  31. Swami Soumya, S.B.; Sawant, A.A.; Khandetod, Y.P.; Mohod, A.G.; Dhekale, J.S. Extraction methods used for extraction of anthocyanin: A review. Pharma Innov. J. 2019, 8, 280–285. [Google Scholar]
  32. Carpentieri, S.; Režek, J.A.; Ferrari, G.; Pataro, G. Pulsed Electric Field-Assisted Extraction of Aroma and Bioactive Compounds From Aromatic Plants and Food By-Products. Front. Nutr. 2022, 8, 792203. [Google Scholar] [CrossRef]
  33. Puri, M.; Sharma, D.; Barrow, C.J. Enzyme-assisted extraction of bioactives from plants. Trends Biotechnol. 2012, 30, 37–44. [Google Scholar] [CrossRef]
  34. Nieto, A.; Borrull, F.; Pocurull, E.; Marce, R.M. Pressurized liquid extraction: A useful technique to extract pharmaceuticals and personal-care products from sewage sludge. TrAC Trends Anal. Chem. 2010, 29, 752–764. [Google Scholar] [CrossRef]
  35. Levaya, Y.K.; Zholdasbayev, M.E.; Atazhanova, G.A.; Akhmetova, S.B.; Ishmuratova, M.Y. Antibacterial activity of ultrasonic extracts of Salvia stepposa growing in Kazakhstan. Bull. Karaganda Univ. Ser. Biol. Med. Geogr. 2021, 1, 45–49. [Google Scholar] [CrossRef]
  36. Levaya, Y.K.; Zholdasbayev, M.E.; Atazhanova, G.A.; Akhmetova, S.B. Evaluation of Antibacterial Activity of Salvia stepposa Extracts Isolated using Microwave Extraction, Growing Wild in Kazakhstan. Trends Sci. 2022, 19, 3217. [Google Scholar] [CrossRef]
  37. Ji, J.B.; Lu, X.H.; Cai, M.Q.; Xu, Z.C. Improvement of leaching process of Geniposide with ultrasound. Ultrason. Sonochem 2006, 13, 455–462. [Google Scholar] [CrossRef]
  38. Gaete-Garretón, L.; Vargas-Hernández, Y.; Cares-Pacheco, M.G.; Sainz, J.; Alarcón, J. Ultrasonically enhanced extraction of bioactive principles from Quillaja Saponaria Molina. Ultrasonics 2011, 51, 581–585. [Google Scholar] [CrossRef]
  39. Guowen, Z.; Li, H.; Hu, M. Optimized ultrasonic-assisted extraction of flavonoids from Prunella vulgaris L. and evaluation of antioxidant activities in vitro. Innov. Food Sci. Emerg. Technol. 2011, 12, 18–25. [Google Scholar] [CrossRef]
  40. Groșan, A.; Stefănescu, R.; Gurzu, S.; Muntean, D.; Vlase, L.; Vari, C. Study of the potential antiulcerous action of hydroalcoholic extracts from Prunella vulgaris L. of romanian origin. Farmacia 2020, 68, 5. [Google Scholar] [CrossRef]
  41. Mak, W.; Walsh, S. The Characterization of Steam Distillation as an Extraction Method to Extract Volatile Compounds from Prunella vulgaris and the Investigation of Their Anti-Tumorous Effect. J. Biosci. Med. 2021, 9, 120–142. [Google Scholar] [CrossRef]
  42. Xia, B.H.; Xiong, S.H.; Tang, J.; Zhang, Z.M.; Li, Y.M.; Li, M.J.; Lin, L.M. Extraction of flavonoids in Prunella vulgaris based on deep eutectic solvent method: Application of new green solvent. Zhongguo Zhong Yao Za Zhi 2018, 43, 3484–3492. (In Chinese) [Google Scholar] [CrossRef] [PubMed]
  43. Alupului, A.; Călinescu, I.; Lavric, V. Microwave extraction of active principles from medicinal plants. U.P.B. Sci. Bull. Series B 2012, 74, 129–142. [Google Scholar]
  44. Bagade, S.B.; Patil, M. Recent Advances in Microwave Assisted Extraction of Bioactive Compounds from Complex Herbal Samples: A Review. Crit. Rev. Anal. Chem. 2021, 51, 138–149. [Google Scholar] [CrossRef] [PubMed]
  45. Akhtar, I.; Javad, S.; Yousaf, Z.; Iqbal, S.; Jabeen, K. Review: Microwave assisted extraction of phytochemicals an efficient and modern approach. Pak. J. Pharm. Sci. 2019, 32, 223–230. [Google Scholar] [PubMed]
  46. Zhang, X.R.; Chen, Y.H.; Guo, Q.S.; Wang, W.M.; Liu, L.; Fan, J. Short-term UV-B radiation effects on morphology, physiological traits and accumulation of bioactive compounds in Prunella vulgaris L. J. Plant Interact. 2017, 12, 348–354. [Google Scholar] [CrossRef]
  47. Chen, Y.; Zhang, X.; Guo, Q.; Cao, L.; Qin, Q.; Li, C.; Zhao, M.; Wang, W. Plant morphology, physiological characteristics, accumulation of secondary metabolites and antioxidant activities of Prunella vulgaris L. under UV solar exclusion. Biol. Res. 2019, 52, 17. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  48. Li, C.; Huang, Q.; Fu, X.; Yue, X.J.; Liu, R.H.; You, L.J. Characterization, antioxidant and immunomodulatory activities of polysaccharides from Prunella vulgaris Linn. Int. J. Biol. Macromol. 2015, 75, 298–305. [Google Scholar] [CrossRef] [PubMed]
  49. Sun, H.X.; Qin, F.; Pan, Y.J. In vitro and in vivo immunosuppressive activity of Spica Prunellae ethanol extract on the immune responses in mice. J. Ethnopharmacol. 2005, 101, 31–36. [Google Scholar] [CrossRef]
  50. Fazal, H.; Abbasi, B.H.; Ahmad, N.; Ali, S.S.; Akbar, F.; Kanwal, F. Correlation of different spectral lights with biomass accumulation and production of antioxidant secondary metabolites in callus cultures of medicinally important Prunella vulgaris L. J. Photoch. Photobio. B 2016, 159, 1–7. [Google Scholar] [CrossRef]
  51. Myadelets, M.A.; Kukushkina, T.A.; Barsukova, I.N. The content of biologically active substances in Prunella vulgaris L. (lamiaceae) depending on the phase of development. Sib. Med. J. 2014, 127, 102–105. [Google Scholar]
  52. Qiu, H.; Zhang, J.; Guo, Q.; Zhang, Y.; Zhong, X. Prunella vulgaris L. attenuates experimental autoimmune thyroiditis by inducing indoleamine 2,3-dioxygenase 1 expression and regulatory T cell expansion. Biomed. Pharmacother. 2020, 128, 110288. [Google Scholar] [CrossRef]
  53. Yang, A.; Zheng, Z.; Liu, F.; Liu, J.; Wang, R.; Yang, H.; Huang, Z.; Huang, P.; Liu, H. Screening for Potential Antibreast Cancer Components from Prunellae Spica Using MCF-7 Cell Extraction Coupled with HPLC-ESI-MS/MS. Nat. Prod. Commun. 2020, 15, 1–5. [Google Scholar] [CrossRef]
  54. Plugatar, Y.V.; Shevchuk, O.M.; Logvinenko, L.A. Species of the genus Prunella vulgaris L. are sources of valuable biologically active substances. Agrar. Bull. Ural. 2017, 8, 37–45. [Google Scholar]
  55. Golembiovska, O.; Tsurkan, A.; Vynogradov, B. Components of Prunella vulgaris L. Grown in Ukraine. J. Pharmacogn. Phytochem. 2014, 2, 140–146. [Google Scholar]
  56. Sárosi, S.; Bernáth, J.; Burchi, G.; Antonetti, M.; Bertoli, A.; Pistelli, L.; Benvenuti, S. Effect of different plant origins and climatic conditions on the total phenolic content and total antioxidant capacity of self-heal (Prunella vulgaris L.). Acta Hortic. 2011, 925, 49–55. [Google Scholar] [CrossRef]
  57. Şahin, S.; Işık, E.; Demir, C. Prediction of Total Phenolic Content in Extracts of Prunella Species from HPLC Profiles by Multivariate Calibration. Int. Sch. Res. Not. 2012, 2012, 120780. [Google Scholar]
  58. Ahn, E.Y.; Lee, Y.J.; Park, J.; Chun, P.; Park, Y. Antioxidant Potential of Artemisia capillaris, Portulaca oleracea, and Prunella vulgaris Extracts for Biofabrication of Gold Nanoparticles and Cytotoxicity Assessment. Nanoscale Res. Lett. 2018, 13, 348. [Google Scholar] [CrossRef]
  59. Tosun, M.N.; Demirel Zorba, N.N.; Yüceer, Y. The anti-quorum sensing and antitumor activity of Prunella vulgaris, Sambucus nigra, Calendula officinalis: Potential use in food industry: Potential use in food industry. J. Microbiol. Biotechnol. Food Sci. 2021, 10, e2774. [Google Scholar] [CrossRef]
  60. Mahboubi, M.; Mahboubi, A.; Kazempour, N. The antimicrobial activity of Prunella vulgaris extracts. Herba Pol. 2015, 61, 31–38. [Google Scholar] [CrossRef] [Green Version]
  61. Gazanfar, A.; Mubashir, H.M.; Nahida, T.; Sameer, A.M.; Mir, J.I. In vivo hepatoprotective potential of extracts obtained from floral spikes of Prunella vulgaris L. J. Ayurveda Integr. Med. 2020, 11, 502–507. [Google Scholar] [CrossRef]
  62. Rasool, R.; Ganai, B.A. Prunella vulgaris L.: A Literature Review on its Therapeutic Potentials. Pharmacologia 2013, 4, 441–448. [Google Scholar] [CrossRef] [Green Version]
  63. Chi Keung Mak, W.; Walsh, S. The Anti-Viral Activity of Prunella vulgaris: A Narrative Review. Integr. Med. Rep. 2022, 1, 107–122. [Google Scholar] [CrossRef]
  64. Behl, T.; Rocchetti, G.; Chadha, S.; Zengin, G.; Bungau, S.; Kumar, A.; Mehta, V.; Uddin, M.S.; Khullar, G.; Setia, D.; et al. Phytochemicals from Plant Foods as Potential Source of Antiviral Agents: An Overview. Pharmaceuticals 2021, 14, 381. [Google Scholar] [CrossRef] [PubMed]
  65. Ao, Z.; Chan, M.; Ouyang, M.J.; Olukitibi, T.A.; Mahmoudi, M.; Kobasa, D.; Yao, X. Identification and evaluation of the inhibitory effect of Prunella vulgaris extract on SARS-coronavirus 2 virus entry. PLoS ONE 2021, 16, e0251649. [Google Scholar] [CrossRef] [PubMed]
  66. Ao, Z.; Chan, M.; Jing Ouyang, M.; Titus Abiola, O.; Mahmoudi, M.; Kobasa, D.; Yao, X. Prunella vulgaris extract and suramin block SARS-coronavirus 2 virus Spike protein D614 and G614 variants mediated receptor association and virus entry in cell culture system. bioRxiv 2020, 270306. [Google Scholar] [CrossRef]
  67. Groşan, A.; Vari, C.; Ştefănescu, R.; Danciu, C.; Pavel, I.; Dehelean, C.; Man, A.; David, R.; Vlase, L.; Muntean, L. Antibacterial and antitumor activity of the species Prunella vulgaris L. Rev. Romana Med. Lab. 2020, 28, 405–417. [Google Scholar] [CrossRef]
  68. Man, A.; Gâz Florea, S.A.; Mare, A.D.; Berta, L. Effects of low-molecular weight alcohols on bacterial viability. Rev. Romana Med. Lab. 2017, 25, 335–343. [Google Scholar] [CrossRef] [Green Version]
  69. Patel, J.K.; Joshi, C.K.; Sharma, M.K. Prunella vulgaris L. Potentiates Answer to the Emergence of Dreaded Antibiotic Resistance. J. Pure Appl. Microbiol. 2021, 15, 1429–1441. [Google Scholar] [CrossRef]
  70. Zhao, J.; Ji, D.; Zhai, X.; Zhang, L.; Luo, X.; Fu, X. Oral Administration of Prunella vulgaris L Improves the Effect of Taxane on Preventing the Progression of Breast Cancer and Reduces Its Side Effects. Front. Pharmacol. 2018, 9, 806. [Google Scholar] [CrossRef]
  71. Feng, L.; Jia, X.; Zhu, M.M.; Chen, Y.; Shi, F. Antioxidant activities of total phenols of Prunella vulgaris L. in vitro and in tumor-bearing mice. Molecules 2010, 15, 9145–9156. [Google Scholar] [CrossRef]
  72. Chen, Y.; Zhang, X.; Guo, Q.; Liu, L.; Li, C.; Cao, L.; Qin, Q.; Zhao, M.; Wang, W. Effects of UV-B Radiation on the Content of Bioactive Components and the Antioxidant Activity of Prunella vulgaris L. Spica during Development. Molecules 2018, 23, 989. [Google Scholar] [CrossRef] [Green Version]
  73. Seo, J.K.; Kang, M.-J.; Shin, J.-H.; Lee, S.-J.; Jeong, H.-G.; Sung, N.-J.; Chung, Y.-C. Antibacterial and antioxidant activities of solvent extracts from different parts of hagocho (Prunella vulgaris). J. Korean Soc. Food. Sci. Nutr. 2010, 39, 1425–1432. [Google Scholar] [CrossRef]
  74. Ohanyan, A.D.; Shishkoyan, N.D.; Kazaryan, S.A.; Hovhannisyan, A.A.; Tiratsuyan, S.G.; Elbekyan, K.S.; Koshel, V.I.; Khodzhayan, A.B. Antioxidant and hemolytic properties of different extracts from Prunella vulgaris L. leaves. Med. Bull. North Cauc. 2018, 13, 507–510. [Google Scholar] [CrossRef]
  75. Zhang, W.; Wuhan, Q.; Na, M.; Hu, R.; Mu, Q.; Bao, X. Emerging therapeutic role of Prunella vulgaris in thyroid disease. Chin. Herb. Med. 2022, 14, 403–413. [Google Scholar] [CrossRef] [PubMed]
  76. Han, Q.; Xu, N.; Chen, B.; Wu, W.; Sheng, L. Safety and efficacy of Prunella vulgaris preparation in adjuvant treatment of thyroid nodules: A meta-analysis. Medicine 2021, 100, e27490. [Google Scholar] [CrossRef] [PubMed]
  77. Gan, X.X.; Zhong, L.K.; Shen, F.; Feng, J.H.; Li, Y.Y.; Li, S.J.; Cai, W.S.; Xu, B. Network Pharmacology to Explore the Molecular Mechanisms of Prunella vulgaris for Treating Hashimoto’s Thyroiditis. Front. Pharmacol. 2021, 12, 700896. [Google Scholar] [CrossRef]
  78. Shen, X.; Yang, R.; An, J.; Zhong, X. Analysis of the Molecular Mechanisms of the Effects of Prunella vulgaris against Subacute Thyroiditis Based on Network Pharmacology. Evid. Based Complement. Altern. Med. 2020, 2020, 9810709. [Google Scholar] [CrossRef]
  79. Li, B.; Guo, J.; Wang, F.; Cheng, S.; Zeng, L. Effect of Prunella vulgaris polysaccharides on cultured orbit fibroblasts in vitro from patients with thyroid-associated ophthalmopathy. Exp. Eye Res. 2020, 201, 108276. [Google Scholar] [CrossRef] [PubMed]
  80. Li, B.Y.; Hu, Y.; Li, J.; Shi, K.; Shen, Y.F.; Zhu, B.; Wang, G.X. Ursolic acid from Prunella vulgaris L. efficiently inhibits IHNV infection in vitro and in vivo. Virus Res. 2019, 273, 197741. [Google Scholar] [CrossRef] [PubMed]
  81. Gu, X.; Li, Y.; Mu, J.; Zhang, Y. Chemical constituents of Prunella vulgaris. J. Environ. Sci. 2013, 25 (Suppl. S1), S161–S163. [Google Scholar] [CrossRef] [PubMed]
  82. Eskova, A.Y.; Kubyshkin, A.V.; Fomochkina, I.I. Ointment for the Treatment of Burns. Federal State Autonomous Educational Institution of Higher Education; M.V. Frunze Crimean University: Crimea, Russia, 2012. [Google Scholar]
  83. Gong, X.J.; Liu, W.G.; Zhong, H. Prunella tablets treatment of benign prostatic hyperplasia in 40 cases. J. Pract. Tradit. Chin. Med. 2014, 30, 964–965. [Google Scholar]
  84. Mo, Y.T.; Liu, P. Clinical study of prunella combined with glucocorticoids on subacute thyroiditis. Asia-Pac. Tradit. Med. 2015, 11, 119–120. [Google Scholar]
  85. Fan, Z.Y.; Zhang, L.L.; Mi, R. Effect of Xiakucao capsule on Hashimoto thyroiditis and the ultrasonic diagnosis of thyroid morphology before and after treatment. J. Hebei Med. Univ. 2017, 38, 446–449. [Google Scholar] [CrossRef]
Figure 1. Appearance of Prunella vulgaris at the flowering stage.
Figure 1. Appearance of Prunella vulgaris at the flowering stage.
Pharmaceuticals 16 01106 g001
Table 2. Chemical compositions of different plant parts of Prunella vulgaris.
Table 2. Chemical compositions of different plant parts of Prunella vulgaris.
Compound NameRTMethodSolventPlant PartReference
1Gluconic acid
Pharmaceuticals 16 01106 i001
0.88UPLC-ESI-MSWaterSpike[47]
2Malic acid
Pharmaceuticals 16 01106 i002
1.05UPLC-ESI-MSWaterSpike[47]
3Citric acid
Pharmaceuticals 16 01106 i003
1.26UPLC-ESI-MSWaterSpike[47]
6.58UPLC-MS/MSEthanol/WaterWhole plant[27]
4Caftaric acid
Pharmaceuticals 16 01106 i004
2.10HPLC-UV/MSMethanol/WaterSeed[36]
5Gentisic acid
Pharmaceuticals 16 01106 i005
2.15HPLC-UV/MSMethanol/WaterSeed[36]
6Danshensu
Pharmaceuticals 16 01106 i006
2.62UPLC-MS/MSEthanol/WaterWhole plant[27]
7Long-chain fatty acid
Pharmaceuticals 16 01106 i007
2.65UPLC-ESI-MSWaterSpike[47]
8Protocatechuic acid
Pharmaceuticals 16 01106 i008
3.25UPLC-ESI-MSWaterSpike[47]
5.79HPLC-ESI-MS/MWaterSpike[48]
9m-Dimethylbenzene
Pharmaceuticals 16 01106 i009
4.76GC-MSEthyl acetateSpike[30]
10Protocatechuic aldehyde
Pharmaceuticals 16 01106 i010
5.85UPLC-ESI-MSWaterSpike[47]
7.06HPLC-ESI-MS/MWaterSpike[48]
11Chlorogenic acid
Pharmaceuticals 16 01106 i011
5.01UPLC-MS/MSEthanol/WaterWhole plant[27]
5.6HPLC-UV/MSMethanol/WaterSeed[36]
13.01HPLCEthanol/WaterAerial part[49]
12Thymine
Pharmaceuticals 16 01106 i012
5.39GC-MSMethanolWhole plant[29]
13Dihydrocaffeic acid
Pharmaceuticals 16 01106 i013
5.65UPLC-MS/MSEthanol/WaterWhole plant[27]
14Caffeic acid
Pharmaceuticals 16 01106 i014
5.6HPLC-UV/MSMethanol/WaterSeed[36]
6.67UPLC-MS/MSEthanol/WaterWhole plant[27]
8.46HPLC-ESI-MS/MWaterSpike[48]
9.17UPLC-ESI-MSWaterSpike[47]
14.08HPLCEthanol/WaterAerial part [49]
20.99HPLCMethanolSeed[22]
15Esculetin
Pharmaceuticals 16 01106 i015
5.85UPLC-MS/MSEthanol/WaterWhole plant[27]
16Trans-caran
Pharmaceuticals 16 01106 i016
6.13GC-MSHexaneWhole plant[29]
172-dodecan
Pharmaceuticals 16 01106 i017
6.2GC-MSEthyl acetateWhole plant[29]
18Coumaran
Pharmaceuticals 16 01106 i018
6.43GC-MSMethanolWhole plant[29]
195-hydroxymethylfurfural
Pharmaceuticals 16 01106 i019
6.53GC-MSMethanolWhole plant[29]
20Carvacrol
Pharmaceuticals 16 01106 i020
7.05GC-MSHexaneWhole plant[29]
7.14GC-MSEthyl acetateWhole plant[29]
21Thymol
Pharmaceuticals 16 01106 i021
7.05GC-MSEthyl acetateWhole plant[29]
7.14GC-MSHexaneWhole plant[29]
22Eugenol methylether
Pharmaceuticals 16 01106 i022
8.25GC-MSMethanolWhole plant[29]
23P-Coumaric acid
Pharmaceuticals 16 01106 i023
8.7HPLC-UV/MSMethanol/WaterSeed[27]
242-hydroxy-5-methylbenzaldehyde
Pharmaceuticals 16 01106 i024
8.7GC-MSMethanolWhole plant[29]
25D-Limonene
Pharmaceuticals 16 01106 i025
8.5GC-MSWaterRoots[50]
9.61GC-MSEthyl acetateSpike[30]
26Mangiferin
Pharmaceuticals 16 01106 i026
9.96UPLC-MS/MSEthanol/WaterWhole plant[27]
27Isorosmarinic acid glycoside
Pharmaceuticals 16 01106 i027
10.05UPLC-ESI-MSWaterSpike[47]
28Scopoletin
Pharmaceuticals 16 01106 i028
10.78UPLC-MS/MSEthanol/WaterWhole plant[27]
29Rosmarinic acid
Pharmaceuticals 16 01106 i029
10.88UPLC-ESI-MSWaterSpike[47]
12.08HPLC-ESI-MS/MWaterSpike[48]
20.51HPLCEthanol/WaterAerial part [49]
21.09UPLC-MS/MSEthanol/WaterWhole plant[27]
33.1HPLCMethanolSeed[22]
30Linalool
Pharmaceuticals 16 01106 i030
11.48GC-MSEthyl acetateRoots[50]
31Ferulic acid
Pharmaceuticals 16 01106 i031
12.10UPLC-MS/MSEthanol/WaterWhole plant[27]
12.2HPLC-UV/MSMethanol/WaterSeed[36]
32Ursolic acid
Pharmaceuticals 16 01106 i032
12.10
47.21
UPLC-ESI-MS
UPLC-ESI-MS
Water
Ethanol/Water
Spike
Whole plant
[47]
[27]
33Isoorientin
Pharmaceuticals 16 01106 i033
12.47UPLC-MS/MSEthanol/WaterWhole plant[27]
34Dihydroferulic acid
Pharmaceuticals 16 01106 i034
14.05UPLC-MS/MSEthanol/WaterWhole plant[27]
35Caprylic acid
Pharmaceuticals 16 01106 i035
14.13GC-MSEthyl acetateLeaves[50]
36Jacoesidin
Pharmaceuticals 16 01106 i036
14.58UPLC-MS/MSEthanol/WaterWhole plant[27]
37Cynaroside
Pharmaceuticals 16 01106 i037
15.88UPLC-MS/MSEthanol/WaterWhole plant[27]
38Hyperoside
Pharmaceuticals 16 01106 i038
16.26UPLC-MS/MSEthanol/WaterWhole plant[27]
18.6HPLC-UV/MSMethanol/WaterSeed[36]
39Rutin
Pharmaceuticals 16 01106 i039
16.92UPLC-MS/MSEthanol/WaterWhole plant[27]
19.76HPLCEthanol/WaterAerial part [49]
20.2HPLC-UV/MSMethanol/WaterSeed[36]
40Lavandulol acetate
Pharmaceuticals 16 01106 i040
17.26GC-MSEthyl acetateWhole plant[29]
41β-Cyclocitrale
Pharmaceuticals 16 01106 i041
17.31GC-MSEthyl acetateLeaves[50]
42Salviaflaside
Pharmaceuticals 16 01106 i042
17.76UPLC-MS/MSEthanol/WaterWhole plant[27]
29.2HPLCMethanolSeed[22]
43Genistein
Pharmaceuticals 16 01106 i043
18.5UPLC-MS/MSEthanol/WaterWhole plant[27]
44Hesperidin
Pharmaceuticals 16 01106 i044
19.08UPLC-MS/MSEthanol/WaterWhole plant[27]
45Isoquercitrin
Pharmaceuticals 16 01106 i045
19.6HPLC-UV/MSMethanol/WaterSeed[36]
46Abscisic acid
Pharmaceuticals 16 01106 i046
19.19UPLC-MS/MSEthanol/WaterWhole plant[27]
47Kaempferol-7-O-glucoside
Pharmaceuticals 16 01106 i047
19.56UPLC-MS/MSEthanol/WaterWhole plant[27]
48β-Bourbonene
Pharmaceuticals 16 01106 i048
19.98GC-MSEthyl acetateLeaves[50]
49Quercitin
Pharmaceuticals 16 01106 i049
20.24HPLCEthanol/WaterAerial part [49]
23.0HPLC-UV/MSMethanol/WaterSeed[36]
50Methyl caffeate
Pharmaceuticals 16 01106 i050
21.22UPLC-MS/MSEthanol/WaterWhole plant[27]
51β-Farnesene
Pharmaceuticals 16 01106 i051
21.56GC-MSEthyl acetateRoots[50]
52Humulene
Pharmaceuticals 16 01106 i052
22.01GC-MSEthyl acetateRoots[50]
53γ-Nonalactone (Prunolide)
Pharmaceuticals 16 01106 i053
22.31GC-MSEthyl acetateStems[50]
54Geranyl acetone
Pharmaceuticals 16 01106 i054
22.53GC-MSEthyl acetateStems[50]
55Germacren D
Pharmaceuticals 16 01106 i055
22.66GC-MSEthyl acetateLeaves[50]
56Cyanidin
Pharmaceuticals 16 01106 i056
24.97UPLC-MS/MSEthanol/WaterWhole plant[27]
57Phytol
Pharmaceuticals 16 01106 i057
25.13GC-MSEthyl acetateWhole plant[29]
25.15GC-MSMethanolWhole plant[29]
58Spathulenol
Pharmaceuticals 16 01106 i058
25.23GC-MSEthyl acetateFlowers, leaves[50]
59Ethyl caffeate
Pharmaceuticals 16 01106 i059
25.34UPLC-MS/MSEthanol/WaterWhole plant[27]
60Quercetol
Pharmaceuticals 16 01106 i060
26.8HPLC-UV/MSMethanol/WaterSeed[36]
61Myristic acid
Pharmaceuticals 16 01106 i061
27.15GC-MSEthyl acetateLeaves, stems, roots[50]
62Acacetin
Pharmaceuticals 16 01106 i062
27.81UPLC-MS/MSEthanol/WaterWhole plant[27]
63Methyl rosinate
Pharmaceuticals 16 01106 i063
28.44UPLC-MS/MSEthanol/WaterWhole plant[27]
64Pentadecane
Pharmaceuticals 16 01106 i064
28.80GC-MSEthyl acetateSpike[30]
65Luteolin
Pharmaceuticals 16 01106 i065
29.64UPLC-MS/MSEthanol/WaterWhole plant[27]
66Kaempferol
Pharmaceuticals 16 01106 i066
31.6HPLC-UV/MSMethanol/WaterSeed[36]
32.79UPLC-MS/MSEthanol/WaterWhole plant[27]
67Ethyl rosemary
Pharmaceuticals 16 01106 i067
32.38UPLC-MS/MSEthanol/WaterWhole plant[27]
68Hexadecane
Pharmaceuticals 16 01106 i068
23.18GC-MSEthyl acetateFlowers, leaves, stems, roots[50]
32.53GC-MSEthyl acetateSpike[30]
69Apigenin
Pharmaceuticals 16 01106 i069
33.1HPLC-UV/MSMethanol/Water Seed[36]
33.51UPLC-MS/MSEthanol/WaterWhole plant[27]
70Daidzein
Pharmaceuticals 16 01106 i070
35.93UPLC-MS/MSEthanol/WaterWhole plant[36]
71Heptadecane
Pharmaceuticals 16 01106 i071
24.84GC-MSEthyl acetateFlowers, leaves, stems, roots, spikes[50]
32.53GC-MSEthyl acetate[30]
72Amolsamic acid A
Pharmaceuticals 16 01106 i072
40.2HPLCMethanolSeed[22]
73Amolsamic acid B
Pharmaceuticals 16 01106 i073
41.6HPLCMethanolSeed[22]
74Prunelloside A
Pharmaceuticals 16 01106 i074
46.09UPLC-MS/MSEthanol/WaterWhole plant[27]
75Maslinic acid
Pharmaceuticals 16 01106 i075
46.33UPLC-MS/MSEthanol/WaterWhole plant[27]
76Corosolic acid
Pharmaceuticals 16 01106 i076
46.74UPLC-MS/MSEthanol/WaterWhole plant[27]
77Oleanic acid
Pharmaceuticals 16 01106 i077
46.95UPLC-MS/MSEthanol/WaterWhole plant[27]
78Linolenic acid
Pharmaceuticals 16 01106 i078
25.90GC-MSMethanolWhole plant[29]
25.92GC-MSEthyl acetateWhole plant[29]
25.99GC-MSHexaneWhole plant[29]
47.02UPLC-MS/MSEthanol/WaterWhole plant[27]
79Linoleic acid
Pharmaceuticals 16 01106 i079
25.70GC-MSMethanolWhole plant[29]
25.72GC-MSEthyl acetateWhole plant[29]
25.79GC-MSHexaneWhole plant[29]
47.45UPLC-MS/MSEthanol/WaterWhole plant[27]
51.18GC-MSEthyl acetateSpike[30]
80Palmitic acid
Pharmaceuticals 16 01106 i080
20.73GC-MMethanolWhole plant[29]
20.74GC-MSEthyl acetateWhole plant[29]
20.8GC-MSHexaneWhole plant[29]
29.84GC-MSEthyl acetateLeaves[50]
45.67GC-MSEthyl acetateSpike[30]
47.90UPLC-MS/MSEthanol/WaterWhole plant[27]
81Oleic acid
Pharmaceuticals 16 01106 i081
32.15GC-MSEthyl acetateLeaves, roots[50]
48.01UPLC-MS/MSEthanol/WaterWhole plant[27]
82Stearic acid
Pharmaceuticals 16 01106 i082
26.52GC-MSEthyl acetateWhole plant[29]
26.55GC-MSMethanolWhole plant[29]
48.82UPLC-MS/MSEthanol/WaterWhole plant[27]
83Squalene
Pharmaceuticals 16 01106 i083
38.7GC-MSEthyl acetateFlowers, roots[50]
67.36GC-MSEthyl acetateWhole plant[29]
Table 3. Antibacterial activity of Prunella vulgaris extracts.
Table 3. Antibacterial activity of Prunella vulgaris extracts.
Type of ExtractPlant PartStrainMICMBCReference
Organic Fraction of PVHerbS. aureus ATCC3953 256 mg/mL-[8]
S. aureus ATCC4223128 mg/mL-
MethanolicLeavesK. pneumoniae ATCC13883 25 mg/mL50 mg/mL[63]
E. coli ATCC2592250 mg/mL50 mg/mL
P. aeruginosa ATCC2785312.5 mg/mL50 mg/mL
MRSA ATCC 4330025 mg/mL25 mg/mL
FlowersK. pneumoniae ATCC13883 25 mg/mL25 mg/mL[63]
E. coli ATCC2592225 mg/mL25 mg/mL
P. aeruginosa ATCC278536.25 mg/mL25 mg/mL
MRSA ATCC 4330025 mg/mL25 mg/mL
AqueousLeavesK. pneumoniae ATCC13883 >50 mg/mL>50 mg/mL[63]
E. coli ATCC25922>50 mg/mL>50 mg/mL
P. aeruginosa ATCC27853>50 mg/mL>50 mg/mL
MRSA ATCC 43300>50 mg/mL>50 mg/mL
FlowersK. pneumoniae ATCC1388350 mg/mL>50 mg/mL[63]
E. coli ATCC25922 >50 mg/mL>50 mg/mL
P. aeruginosa ATCC2785325 mg/mL>50 mg/mL
MRSA ATCC 43300>50 mg/mL>50 mg/mL
AqueousWhole plantE. coli ATCC259222 μg/mL-[19]
EthanolicWhole plantE.coli ATCC259221.33 μg/mL-[19]
Ethyl acetateWhole plantC. perfringens1.56 μg/mL-[29]
S. aureus6.25 μg/mL-
E. coli0.195 μg/mL-
S. marcescens6.25 μg/mL-
K. pneumoniae0.78 μg/mL-
P. aeruginosa1.56 μg/mL-
HexaneWhole plantC. perfringens6.25 μg/mL-[29]
S. pyogenes3.12 μg/mL-
S. typhimurium1.56 μg/mL-
E. coli6.25 μg/mL-
P. vulgaris3.12 μg/mL-
P. aeruginosa6.25 μg/mL-
MethanolicWhole plantB. cereus1.56 μg/mL-[29]
C. perfringens6.25 μg/mL-
S. marcescens6.25 μg/mL-
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Zholdasbayev, M.E.; Atazhanova, G.A.; Musozoda, S.; Poleszak, E. Prunella vulgaris L.: An Updated Overview of Botany, Chemical Composition, Extraction Methods, and Biological Activities. Pharmaceuticals 2023, 16, 1106. https://doi.org/10.3390/ph16081106

AMA Style

Zholdasbayev ME, Atazhanova GA, Musozoda S, Poleszak E. Prunella vulgaris L.: An Updated Overview of Botany, Chemical Composition, Extraction Methods, and Biological Activities. Pharmaceuticals. 2023; 16(8):1106. https://doi.org/10.3390/ph16081106

Chicago/Turabian Style

Zholdasbayev, Mussa E., Gayane A. Atazhanova, Safol Musozoda, and Ewa Poleszak. 2023. "Prunella vulgaris L.: An Updated Overview of Botany, Chemical Composition, Extraction Methods, and Biological Activities" Pharmaceuticals 16, no. 8: 1106. https://doi.org/10.3390/ph16081106

APA Style

Zholdasbayev, M. E., Atazhanova, G. A., Musozoda, S., & Poleszak, E. (2023). Prunella vulgaris L.: An Updated Overview of Botany, Chemical Composition, Extraction Methods, and Biological Activities. Pharmaceuticals, 16(8), 1106. https://doi.org/10.3390/ph16081106

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop